Skip header and navigation

Refine By

18022 records – page 1 of 1803.

A 1-year follow-up of low birth weight infants with and without bronchopulmonary dysplasia: health, growth, clinical lung disease, cardiovascular and neurological sequelae.

https://arctichealth.org/en/permalink/ahliterature59584
Source
Early Hum Dev. 1992 Sep;30(2):109-20
Publication Type
Article
Date
Sep-1992

A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.

https://arctichealth.org/en/permalink/ahliterature176202
Source
Contraception. 2005 Feb;71(2):111-7
Publication Type
Article
Date
Feb-2005
Author
Sven O Skouby
Jan Endrikat
Bernd Düsterberg
Werner Schmidt
Christoph Gerlinger
Jens Wessel
Henri Goldstein
Joergen Jespersen
Author Affiliation
Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark. sven.skouby@fh.hosp.dk
Source
Contraception. 2005 Feb;71(2):111-7
Date
Feb-2005
Language
English
Publication Type
Article
Keywords
Adult
Blood Glucose - metabolism
C-Peptide - blood
Carbohydrate Metabolism - drug effects
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Contraceptive Agents, Female - administration & dosage - pharmacology
Contraceptives, Oral, Combined - administration & dosage - pharmacology
Denmark
Dose-Response Relationship, Drug
Ethinyl Estradiol - administration & dosage - pharmacology
Fatty Acids, Nonesterified - blood
Female
Humans
Insulin - blood
Levonorgestrel - administration & dosage - pharmacology
Lipid Metabolism - drug effects
Prospective Studies
Time Factors
Treatment Outcome
Triglycerides - blood
Abstract
To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives.
In an open-label, randomized study, a dose-reduced oral contraceptive containing 20 microg EE and 100 microg LNG (20 EE/100 LNG) was compared with a reference preparation containing 30 microg EE and 150 microg LNG (30 EE/150 LNG). One-year data from 48 volunteers were obtained.
We found a decrease of HDL2 cholesterol and increases of low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol and total triglycerides in both treatment groups from baseline to the 13th treatment cycle. Although for four of six variables, the changes in the 20 EE group were lower compared with the 30 EE group, none of the differences between the two treatments were statistically significant. The median values for the fasting levels of insulin, C-peptide and free fatty acids slightly increased or remained unchanged while the fasting glucose levels slightly decreased after 13 treatment cycles. While the glucose area under the curve (AUC) (0-3 h) was similar in both groups during the OGTT, the insulin AUC(0-3 h) was less increased in the 20 EE/100 LNG group compared with the 30 EE/150 LNG group. None of the differences between the treatment groups for any of the carbohydrate metabolism variables were statistically significant at any time point. Both study treatments were safe and well tolerated by the volunteers.
Similar effects on the lipid and carbohydrate profiles were found for both preparations. The balanced one-third EE dose reduction in this new oral contraceptive caused slightly lower, but insignificant, changes in the lipid and carbohydrate variables compared with the reference treatment.
PubMed ID
15707560 View in PubMed
Less detail

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poisoning in Victor Yushchenko: identification and measurement of TCDD metabolites.

https://arctichealth.org/en/permalink/ahliterature95137
Source
Lancet. 2009 Oct 3;374(9696):1179-85
Publication Type
Article
Date
Oct-3-2009
Author
Sorg O.
Zennegg M.
Schmid P.
Fedosyuk R.
Valikhnovskyi R.
Gaide O.
Kniazevych V.
Saurat J-H
Author Affiliation
Dermato-Toxicology, Swiss Centre for Applied Human Toxicology, and Department of Dermatology, University Hospital, Geneva, Switzerland.
Source
Lancet. 2009 Oct 3;374(9696):1179-85
Date
Oct-3-2009
Language
English
Publication Type
Article
Keywords
Adipose Tissue - chemistry
Biopsy
Drug Residues - analysis - metabolism
Fatal Outcome
Feces - chemistry
Forensic Medicine - methods
Half-Life
Homicide
Humans
Male
Middle Aged
Politics
Substance Abuse Detection - methods
Sweat - chemistry
Tetrachlorodibenzodioxin - analysis - chemistry - metabolism - poisoning
Time Factors
Ukraine
Abstract
BACKGROUND: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has a long half-life of 5-10 years in human beings as a result of its high lipophilicity, and little or no metabolism. We monitored TCDD, its form, distribution, and elimination in Victor Yushchenko after he presented with severe poisoning. METHODS: In late December, 2004, a patient presented with TCDD poisoning; the levels in his blood serum (108000 pg/g lipid weight) were more than 50 000-fold greater than those in the general population. We identified TCDD and its metabolites, and monitored their levels for 3 years using gas chromatography and high-resolution mass spectrometry in samples of blood serum, adipose tissue, faeces, skin, urine, and sweat, after they were extracted and cleaned with different organic solvents. FINDINGS: The amount of unmodified TCDD in the samples that were analysed accounted for about 60% of TCDD eliminated from the body during the same period. Two TCDD metabolites-2,3,7-trichloro-8-hydroxydibenzo-p-dioxin and 1,3,7,8-tetrachloro-2-hydroxydibenzo-p-dioxin-were identified in the faeces, blood serum, and urine. The faeces contained the highest concentration of TCDD metabolites, and were the main route of elimination. Altogether, the different routes of elimination of TCDD and its metabolites accounted for 98% of the loss of the toxin from the body. The half-life of TCDD in our patient was 15.4 months. INTERPRETATION: This case of poisoning with TCDD suggests that the design of methods for routine assessment of TCDD metabolites in human beings should be a main aim of TCDD research in the metabolomic era. FUNDING: University of Geneva Dermatology Fund, and Swiss Centre for Applied Human Toxicology.
Notes
Comment In: Lancet. 2009 Oct 3;374(9696):1131-219660808
PubMed ID
19660807 View in PubMed
Less detail

[2 cases of late treatment of decompression sickness].

https://arctichealth.org/en/permalink/ahliterature252342
Source
Gig Tr Prof Zabol. 1975 Apr;(4):44-5
Publication Type
Article
Date
Apr-1975

[2 hours--too careful return to work].

https://arctichealth.org/en/permalink/ahliterature214077
Source
Lakartidningen. 1995 Oct 18;92(42):3868
Publication Type
Article
Date
Oct-18-1995
Author
P. Dahl
Source
Lakartidningen. 1995 Oct 18;92(42):3868
Date
Oct-18-1995
Language
Swedish
Publication Type
Article
Keywords
Humans
Insurance, Health
Rehabilitation, Vocational
Sweden
Time Factors
PubMed ID
7564641 View in PubMed
Less detail

2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus.

https://arctichealth.org/en/permalink/ahliterature121853
Source
Cardiovasc Diabetol. 2012;11:93
Publication Type
Article
Date
2012
Author
Loghman Henareh
Stefan Agewall
Author Affiliation
Department of Cardiology Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. loghman.henareh@karolinska.se
Source
Cardiovasc Diabetol. 2012;11:93
Date
2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Angina, Unstable - blood - epidemiology - mortality
Biological Markers - blood
Blood Glucose - metabolism
Chi-Square Distribution
Female
Glucose Tolerance Test
Humans
Incidence
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction - blood - epidemiology - mortality
Predictive value of tests
Prognosis
Proportional Hazards Models
Prospective Studies
Recurrence
Risk assessment
Risk factors
Smoking - adverse effects - epidemiology
Stroke - blood - epidemiology - mortality
Sweden - epidemiology
Time Factors
Abstract
The incidence of cardiovascular events remains high in patients with myocardial infarction (MI) despite advances in current therapies. New and better methods for identifying patients at high risk of recurrent cardiovascular (CV) events are needed. This study aimed to analyze the predictive value of an oral glucose tolerance test (OGTT) in patients with acute myocardial infarction without known diabetes mellitus (DM).
The prospective cohort study consisted of 123 men and women aged between 31-80 years who had suffered a previous MI 3-12 months before the examinations. The exclusion criteria were known diabetes mellitus. Patients were followed up over 6.03???1.36 years for CV death, recurrent MI, stroke and unstable angina pectoris. A standard OGTT was performed at baseline.
2-h plasma glucose (HR, 1.27, 95% CI, 1.00 to 1.62; P?
Notes
Cites: N Engl J Med. 2000 Jan 20;342(3):145-5310639539
Cites: Cardiovasc Diabetol. 2012;11:2122397368
Cites: Am J Med. 2000 Nov;109(7):538-4211063954
Cites: J Clin Invest. 2001 Aug;108(4):635-611518739
Cites: Diabetologia. 2001 Sep;44 Suppl 2:S54-6411587051
Cites: Circulation. 2001 Nov 27;104(22):2673-811723017
Cites: Diabetes Care. 2001 Dec;24(12):2043-811723080
Cites: BMJ. 2002 Jan 12;324(7329):71-8611786451
Cites: Dtsch Med Wochenschr. 2002 May 3;127(18):953-711987015
Cites: Eur Heart J. 2002 Aug;23(16):1267-7512175663
Cites: Diabetes Care. 2002 Oct;25(10):1845-5012351489
Cites: Int J Cardiol. 2004 Oct;97(1):21-415336801
Cites: Eur Heart J. 1985 Mar;6(3):199-2262863148
Cites: J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-672698218
Cites: Am J Hypertens. 1994 Jul;7(7 Pt 1):615-227946163
Cites: Lancet. 1994 Nov 19;344(8934):1383-97968073
Cites: BMJ. 1995 Mar 4;310(6979):555-97888928
Cites: Diabetes Care. 1996 Mar;19(3):257-678742574
Cites: Diabetologia. 1996 Dec;39(12):1577-838960845
Cites: Diabetes Care. 1998 Sep;21(9):1529-339727904
Cites: Circ Res. 1999 Mar 19;84(5):489-9710082470
Cites: Diabetes Care. 1999 Jun;22(6):920-410372242
Cites: J Am Coll Cardiol. 1999 Jul;34(1):146-5410400004
Cites: Lancet. 1999 Aug 21;354(9179):617-2110466661
Cites: Eur Heart J. 2004 Nov;25(22):1990-715541834
Cites: Am J Cardiol. 2005 Aug 1;96(3):363-516054458
Cites: Diabet Med. 2005 Sep;22(9):1212-716108851
Cites: Clin Ther. 2005;27 Suppl B:S42-5616519037
Cites: Clin Physiol Funct Imaging. 2007 Jan;27(1):60-617204040
Cites: Circ J. 2007 Jun;71(6):834-4117526977
Cites: Circulation. 2007 Jul 10;116(2):151-717576864
Cites: Circulation. 2007 Nov 27;116(22):2634-5317951284
Cites: Heart Vessels. 2009 Mar;24(2):90-519337791
Cites: Prim Care Diabetes. 2009 Nov;3(4):205-919875348
Cites: Diabetes Care. 2010 Jan;33 Suppl 1:S62-920042775
Cites: Cardiovasc Diabetol. 2010;9:7521070650
Cites: Cardiovasc Diabetol. 2011;10:5621702911
Cites: Hypertension. 2000 Aug;36(2):245-910948085
PubMed ID
22873202 View in PubMed
Less detail

[2 outbreaks of trichinelliasis in Rostov Province].

https://arctichealth.org/en/permalink/ahliterature220244
Source
Med Parazitol (Mosk). 1993 Oct-Dec;(5):18-21
Publication Type
Article
Author
V A Dotsenko
T I Tverdokhlebov
A A Shirinian
N G Barinova
A P Ordyntseva
S A Nagornyi
A V Markin
S Ia Verkholomova
E P Tikhomirova
Source
Med Parazitol (Mosk). 1993 Oct-Dec;(5):18-21
Language
Russian
Publication Type
Article
Keywords
Adolescent
Adult
Child
Child, Preschool
Disease Outbreaks - statistics & numerical data
Female
Humans
Infant
Male
Mebendazole - therapeutic use
Middle Aged
Russia - epidemiology
Time Factors
Trichinellosis - diagnosis - drug therapy - epidemiology
Abstract
Two epidemiologically unrelated outbreaks of trichinellosis were registered in Rostov Province in the November and December of 1984 with 16 patients in the Salsk District and 20 patients in Rostov-on-Don. The course of the disease was characterized by 6-20% of severe and 31-45% moderate forms, respectively. The source of the infection was pork that had not been controlled for Trichinella spiralis. Late diagnosis and inadequate treatment in one case led to a fatal outcome. Economic losses accounted for 490,000 rubles (as of 1985). In spite of energetic prophylaxis measures, the situation in the Rostov Province continues to be serious. In 1989-1992, eighteen cases of trichinellosis were registered in the Salsk District again.
PubMed ID
8127264 View in PubMed
Less detail

A 2-year follow-up of 120 Swedish female alcoholics treated early in their drinking career: prediction of drinking outcome.

https://arctichealth.org/en/permalink/ahliterature10097
Source
Alcohol Clin Exp Res. 2001 Nov;25(11):1586-93
Publication Type
Article
Date
Nov-2001
Author
B. Haver
L. Dahlgren
A. Willander
Author Affiliation
Karolinska Institute, Department of Clinical Neuroscience, Clinical Alcohol and Drug Research Section, Stockholm, Sweden. brit.haver@psyk.uib.no
Source
Alcohol Clin Exp Res. 2001 Nov;25(11):1586-93
Date
Nov-2001
Language
English
Publication Type
Article
Keywords
Adult
Aged
Alcoholism - therapy
Biological Markers
Female
Follow-Up Studies
Humans
Middle Aged
Patient compliance
Patient Dropouts
Recurrence
Regression Analysis
Sweden
Time Factors
Treatment Outcome
Abstract
BACKGROUND: One hundred twenty women alcoholics recruited to a treatment program called EWA (Early Treatment for Women With Alcohol Addiction) were studied. The selected women were not previously treated for alcohol abuse. METHODS: The women were followed up by use of a structured personal interview, biomarkers sensitive for alcohol abuse (i.e., glutamyl transpeptidase), and questionnaires, by using defined criteria for abstinence, social drinking, satisfactory drinking outcome, and unsatisfactory drinking outcome. RESULTS: Drinking outcome was good (i.e., total abstinence, social drinking, or satisfactory drinking outcome) for 67% of the women during the total follow-up time, by use of strict criteria for relapse. The results were corroborated by the biomarkers. Similar results were reported from two previously studied groups of women from the same department. However, the frequency of abstinence was higher and social drinking was significantly lower among this sample of women. Daily drinking, the use of sedatives, and a long duration of pretreatment alcohol abuse predicted an unfavorable outcome. However, a long duration of outpatient treatment predicted a good outcome, whereas treatment dropout was related to an unsatisfactory drinking outcome. A majority of the women (96%) rated the treatment experience and the treatment program favorably. The overall good results might reflect the selection of the subjects studied. CONCLUSIONS: Improving treatment program adherence would probably improve outcome for the women with an unsatisfactory drinking outcome.
PubMed ID
11707633 View in PubMed
Less detail

A 3-month evaluation of the efficacy of nedocromil sodium in asthma: a randomized, double-blind, placebo-controlled trial of nedocromil sodium conducted by a Canadian multicenter study group.

https://arctichealth.org/en/permalink/ahliterature229565
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Publication Type
Article
Date
Mar-1990
Author
A S Rebuck
S. Kesten
L P Boulet
A. Cartier
D. Cockcroft
J. Gruber
F. Laberge
E. Lee-Chuy
M. Keshmiri
G F MacDonald
Author Affiliation
Edmonton General Hospital, Canada.
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Date
Mar-1990
Language
English
Publication Type
Article
Keywords
Adult
Anti-Inflammatory Agents, Non-Steroidal - adverse effects - therapeutic use
Asthma - drug therapy - physiopathology
Canada
Chronic Disease
Double-Blind Method
Drug Therapy, Combination
Drug Tolerance
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Nedocromil
Peak Expiratory Flow Rate - drug effects - physiology
Quinolones - adverse effects - therapeutic use
Randomized Controlled Trials as Topic
Time Factors
Abstract
Nedocromil sodium is a pyranoquinoline dicarboxylic acid derivative, formulated in a metered-dose inhaler. Because nedocromil sodium has in vitro and in vivo anti-inflammatory properties, it was evaluated in a group of steroid-dependent patients with asthma to observe how well it might be tolerated and for evidence of any beneficial effects. In a double-blind, group-comparative study, 127 patients received nedocromil sodium and 61 received placebo, administered as two puffs of 2 mg, four times per day, for 12 weeks. Ten patients developed adverse reactions, seven receiving active drug and three patients receiving placebo. Two patients of each group withdrew because of worsening asthma. Despite selecting patients whose asthma was stable, when they were receiving established therapeutic regimens that included steroids and bronchodilators, it was found that diary-card symptom scores, morning and evening peak expiratory flow rate values, and inhaled beta-agonist usage all demonstrated slight but significant benefit with addition of nedocromil sodium. It is concluded that the inhaled, anti-inflammatory agent, nedocromil sodium, may be added to asthma-treatment regimens with the reasonable expectation of further modest symptomatic benefit.
PubMed ID
2155958 View in PubMed
Less detail

A 3-year follow-up of sun behavior in patients with cutaneous malignant melanoma.

https://arctichealth.org/en/permalink/ahliterature106960
Source
JAMA Dermatol. 2014 Feb;150(2):163-8
Publication Type
Article
Date
Feb-2014
Author
Luise Winkel Idorn
Pameli Datta
Jakob Heydenreich
Peter Alshede Philipsen
Hans Christian Wulf
Author Affiliation
Dermatological Research Department D92, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Source
JAMA Dermatol. 2014 Feb;150(2):163-8
Date
Feb-2014
Language
English
Publication Type
Article
Keywords
Adult
Case-Control Studies
Denmark
Female
Follow-Up Studies
Health Behavior
Humans
Male
Melanoma - etiology - pathology
Middle Aged
Prospective Studies
Risk factors
Skin Neoplasms - etiology - pathology
Sunlight - adverse effects
Time Factors
Ultraviolet Rays - adverse effects
Abstract
IMPORTANCE UV radiation (UVR) exposure is the primary environmental risk factor for developing cutaneous malignant melanoma (CMM). OBJECTIVE To measure changes in sun behavior from the first until the third summer after the diagnosis of CMM using matched controls as a reference. DESIGN, SETTING, AND PARTICIPANTS Three-year follow-up, observational, case-control study performed from May 7 to September 22, 2009, April 17 to September 15, 2010, and May 6 to July 31, 2011, at a university hospital in Denmark of 21 patients with CMM and 21 controls matched to patients by sex, age, occupation, and constitutive skin type participated in the study. Exposure to UVR was assessed the first and second summers (n=20) and the first and third summers (n=22) after diagnosis. Data from 40 participants were analyzed. MAIN OUTCOMES AND MEASURES Exposure to UVR was assessed by personal electronic UVR dosimeters that measured time-related UVR in standard erythema dose (SED) and corresponding sun diaries (mean, 74 days per participant each participation year). RESULTS Patients' daily UVR dose and UVR dose in connection with various behaviors increased during follow-up (quantified as an increase in daily UVR dose each year; all days: mean, 0.3 SED; 95% CI, 0.05-0.5 SED; days with body exposure: mean, 0.6 SED; 95% CI, 0.07-1.2 SED; holidays: mean, 1.2 SED; 95% CI, 0.3-2.1 SED; days abroad: 1.9 SED; 95% CI, 0.4-3.4 SED; and holidays with body exposure: mean, 2.3 SED; 95% CI, 1.1-3.4 SED). After the second year of follow-up, patients' UVR dose was higher than that of controls, who maintained a stable UVR dose. No difference was found between groups in the number of days with body exposure or the number of days using sunscreen in the second and third years of follow-up. CONCLUSIONS AND RELEVANCE Our findings suggest that patients with CMM do not maintain a cautious sun behavior in connection with an increase in UVR exposure, especially on days with body exposure, when abroad, and on holidays.
PubMed ID
24080851 View in PubMed
Less detail

18022 records – page 1 of 1803.